¾º¼¼±¦¹ÙÍø--¾º¼¼±¦-¾º¼¼±¦¹ÙÍøDOTA2,LOL,CSGOµç¾ºÈüʼ°ÌåÓýÈüʾº²Â

400-010-5556


IL-21ϸ°ûÒò×ÓÔÚ2000Äê±»·¢ÏÖ£¬ÊôÓÚIL-2¼Ò×å³ÉÔ±£¬½á¹¹ÉÏÊÇÒ»ÖÖËĦÁÂÝÐýÊøIÐÍϸ°ûÒò×Ó¡£Ëü¿ÉÒÔͨ¹ýÓÉIL-21RºÍÆÕͨ¦ÃÁ´/IL-2R¦Ã×é³ÉµÄÊÜÌ帴ºÏÌ弤»îÏÂÓÎÐźÅͨ·¡£IL-21ÓɻµÄCD4+ Tϸ°û¡¢NKTϸ°û»òÂËÅݸ¨ÖúÐÔTϸ°û·ÖÃÚ£¬¶ÔÁܰÍϸ°ûºÍ¹ÇËèϸ°û¾ßÓжàÖÖÉúÎïѧЧӦ£¬ÈçÆäÓëÊÜÌå½áºÏºóÄܹ»µ÷½ÚBϸ°ûÔöÖ³£¬·Ö»¯³É½¬Ï¸°ûÀ´Æô¶¯ÃâÒßÓ¦´ð¡£IL-21»¹ÄÜ´Ù½øCD8+ Tϸ°ûºÍNKϸ°ûµÄÔöÖ³¡¢·Ö»¯£¬Ìá¸ßNKϸ°ûµÄɱÉË»îÐÔ¡¾1¡¿¡£

Fig1£ºIL-21µÄÀ´Ô´¼°¹¦ÄÜÄ¿±ê


ÔÚÃâÒßѧ·ÉËÙ·¢Õ¹µÄ±³¾°Ï£¬¿ÆÑ§¼Ò·¢ÏÖIL-21ÓëTϸ°ûÒÔ¼°Bϸ°ûµÄ·ÖÃÚ¹ØÏµÃÜÇУ¬Ì½Ë÷ÕâÆäÖеĵ÷½Úģʽ¿ÉÒÔ°ïÖúÎÒÃÇѰÕÒÉú²ú¸ü¸ßЧµÄÒßÃçÒÔ¼°ÖÎÁÆ×ÔÉíÃâÒß¼²²¡µÄз½·¨¡£¿¹ÌåµÄ²úÉúÒÀÀµÓÚ¿¹Ô­ÌØÒìÐÔBϸ°ûºÍTϸ°ûµÄÏ໥×÷Óã¬Bϸ°ûÏò¿¹Ìå·ÖÃÚϸ°ûµÄ·Ö»¯·¢ÉúÔÚÃâÒ߯÷¹ÙµÄ¶ÀÌØÎ¢½á¹¹Éú·¢ÖÐÐÄ£¨Germinal centers £©£¬IL-21×÷ΪTϸ°ûÑÜÉúµÄ¶àЧÐÔϸ°ûÒò×Ó£¬Í¬Ê±¿ÉÒÔ´Ù½øÉú·¢ÖÐÐÄÐγÉ¡£ÕâÈýÕß´í×Û¸´ÔӵĹØÏµÒýÆðÁËÀ´×ÔĪÄÉʲ´óѧµÄIsaak Quast½ÌÊÚµÄ×¢Ò⣬²¢ÇÒ´øÁìËûµÄÑо¿ÍŶӽøÐÐÁËʵÑé̽¾¿¡£ÎªÁË·ÖÎöͬԴTϸ°ûºÍBϸ°ûµÄÔöÖ³ºÍ·Ö»¯£¬Ñо¿Ð¡×鿪·¢ÁËÒ»ÖÖ¹ý¼Ì×ªÒÆºÍÃâÒßϵͳOT-II-OVA£¬ÕâÖÖϵͳ¿ÉÒÔÔÚµ÷½ÚIL-21ʱ·ÖÎöͬԴTϸ°û¼°Bϸ°ûÔöÖ³Óë·Ö»¯Çé¿ö¡£Ñо¿Ð¡×éÉè¼ÆÁË·ûºÏʵÑéÄ¿µÄµÄ¶ÔÕÕ×éÒÔ¼°ÊµÑé×飬·ÖÎö½á¹ûºó¾ªÏ²µØ·¢ÏÖÓµÓгä×ãIL-21µÄʵÑé×éÖÐCD4+Tϸ°ûÃ÷ÏÔÀ©ÔöºÍ·Ö»¯£¨Fig2£©£¬Õâ˵Ã÷IL-21¿ÉÒÔÖ±½Ó´Ù½øTϸ°ûÔöÖ³²¢·Ö»¯ÎªTfhϸ°û£¬Õâ¸ö¹ý³ÌÖв¢Ã»ÓÐÉæ¼°Bϸ°û¡¾2¡¿¡£ÕâÌáʾÎÒÃÇ£¬IL-21ÊÇ¿ÉÒÔ¶ÀÁ¢×÷ÓÃÓÚTϸ°ûµÄ¡£

Fig2£ºÏà¹ØÊµÑé¼ì²âϸ°ûµÄÀ©ÔöÒÔ¼°·Ö»¯Çé¿ö


ͬʱ¿ÆÑÐС×éÔÚ»ùÒò²ãÃæÒ²½øÐÐÁË̽Ë÷£¬¿ÆÑÐС×é¶ÔʵÑé×éºÍ¶ÔÕÕ×éµÄϸ°û½øÐÐRNA²âÐòת¼×éѧ·ÖÎö£¬ÏÔʾ391¸ö²îÒì±í´ï»ùÒò¡£GSEA·ÖÎöÏÔʾ£¬Ï¸°ûÖÜÆÚ¡¢×ªÂ¼ºÍÐźŴ«µ¼ÊÇÊܲîÒìÓ°Ïì×î´óµÄ;¾¶£¨Fig3A£©¡£Ê¹ÓÃKEGGÊý¾Ý¿âµÄ·ÖÎöÏÔʾ£¬ÔÚIL21³ä×ãµÄOT-II Tϸ°ûÖУ¬Á½¸öÃÜÇÐÏà¹ØµÄͨ·¹ý¶È±í´ï£¬Ò»¸öÓëϵͳÐÔºì°ßÀÇ´¯Ïà¹Ø£¬ÁíÒ»¸öÓëÑ×Ö¢ÐÔ³¦²¡ºÍTh17ϸ°û·Ö»¯Ïà¹Ø£¬Õâ¶¼ÓëÑ×Ö¢·´Ó¦ÃÜÇÐÏà¹Ø¡£½áºÏϸ°ûʵÑéµÄ½á¹û£¬IL-21¶ÔÓÚÂËÅÝTϸ°û·Ö»¯¹ý³ÌÖз¢»Ó×ÅÖØÒªµÄ×÷Óá£Õâ˵Ã÷ IL-21¾ßÓÐË«ÖØ×÷Ó㬼ȿÉÒÔ´Ù½øTϸ°ûÀ©ÔöÒ²¿ÉÒÔ´Ù½øÏòTh17ºÍTfhϸ°ûϵµÄ·Ö»¯£¬ÒÖÖÆÆäÏòTh2·Ö»¯¡£IL-21²»½ö½öÓ°Ïì²úÉúIL-21µÄTϸ°û£¬»¹»á·ÖɢʽӰÏìÆäËûTϸ°û¡£

Fig3£º»ùÒò²ãÃæµÄÐÅÏ¢·ÖÎö½á¹û


ʵÑé½øÐе½´Ë£¬ÎÒÃǶÔÓÚIL-21ÓëBϸ°ûºÍÉú·¢ÖÐÐÄÖ®¼äͬÑù¸Ðµ½ºÃÆæ¡£Ñо¿Ð¡×éÈÏΪIL-21 ¶Ô Tfh ϸ°û·Ö»¯µÄ¹±Ï×È¡¾öÓÚ°éËæBϸ°û·´Ó¦£¬ÒòΪǰÈ˵ÄÑо¿Ö¤Ã÷Éú·¢ÖÐÐĵÄBϸ°û ºÍ Tfh ϸ°û״̬¹ØÏµÃÜÇС¾3¡¿£¬Isaak Quast½ÌÊÚµÄÑо¿½á¹ûÖ¤Ã÷µ±IL-21ÐźŽö×÷ÓÃÓÚTϸ°ûʱ£¬Bϸ°ûÔöÖ³¼°½¬Ï¸°û·Ö»¯×÷ÓÃ×îÃ÷ÏÔ¡£Ïà±ÈÓëBϸ°ûIL-21RÐźÅͨ·£¬Ôö¼ÓTfhϸ°ûÊýÁ¿¿ÉÒÔ¸üºÃµÄ´Ù½øBϸ°ûµÄ·Ö»¯¡£IL-21ͨ¹ýµ÷¿ØTfhϸ°ûµÄÔöÖ³ºÍ·Ö»¯À´Ó°ÏìÉú·¢ÖÐÐĵĴóС£¬IL-21Ҳͬʱµ÷¿ØBϸ°ûÒÔά³Ö¶ÔÉú·¢ÖÐÐĵĵ÷½Ú£¨Fig4£©¡£ÊáÀí×ܽáËùÓÐʵÑ飬֤Ã÷ÁËIL-21¿ÉÒÔ¶ÀÁ¢×÷ÓÃÓÚTϸ°ûÒÔ¼°Bϸ°û£¬²¢½«¶þÕß½áºÏÆðÀ´µ÷½ÚÉú·¢ÖÐÐÄ¡£Õâ¶ÔÓÚÎÒÃÇÉîÈë̽¾¿IL-21ÔÚÃâÒßÁìÓòµÄ×÷Óã¬ÒÔ¼°ºóÐø¿ª·¢¾ßÓÐÖØÒªµÄÒâÒå¡£


Fig4£ºÌ½¾¿IL-21ÓëBϸ°ûÒÔ¼°Éú·¢ÖÐÐÄÖ®¼ä¹ØÏµµÄÏà¹ØÊµÑé


С½á£ºÇ§ìûÄê²Å½øÈë¿ÆÑ§¼ÒÊÓÒ°µÄIL-21£¬Æð²½ºÍÑо¿½øÕ¹ËäÈ»ÂÔÂäºóÓÚͬ¼Ò×åµÄÈÈÃųÉÔ±£¬µ«ÊÇÔÚǰ±²µÄÈüµÀºÍÑо¿ÈÕ½¥Óµ¼·±¥ºÍµÄ½ñÌ죬IL-21ÔÚÃâÒßÖÎÁÆÁìÓòÒ²¿ªÊ¼Õ¸Â¶Í·½Ç£¬ÔÚÖ×Áö΢»·¾³ÁìÓò£¬ÓÐÑо¿Ö¤Ã÷IL-21ÔÚͬÑù·¢»Óϸ°ûɱÉË×÷ÓõÄͬʱ£¬Õ¹ÏÖ³öÃ÷ÏÔµÍÓÚIL-2µÄϸ°û¶¾ÐÔ¡¾4¡¿¡£ÕâÒ»Çж¼ÔÚ°µÊ¾×ÅIL-21¾ßÓо޴óµÄ¿ª·¢ºÍÑо¿¼ÛÖµ£¬°ïÖúÒ©ÆóºÍÑо¿Õß¿ªÍØË¼Î¬±ß½çºÍ̽Ë÷ά¶È¡£


¾º¼¼±¦¹ÙÍøIL-21

¾º¼¼±¦¹ÙÍøGMP¼¶ÖØ×éÈËIL-21µ°°×²ÉÓò¸È鶯ÎïHEK293Ìåϵ±í´ï£¬µ°°×ÓëÌìÈ»µ°°×µÄ½á¹¹¡¢ÌÇ»ù»¯ÀàÐͺͷ½Ê½¼¸ºõÍêÈ«Ïàͬ£¬²¢ÇÒÔÚµ°°×ºÏ³ÉÆðʼÐźÅ¡¢¼Ó¹¤¡¢·ÖÃڵȷ½Ãæ¾ßÓжÀÌØÓÅÊÆ£¬¾ßÓеÍÄÚ¶¾ËØ¡¢¸ß´¿¶È¡¢¸ß»îÐÔ¡¢¸ßÅú¼äÒ»ÖÂÐÔµÈÌØµã¡£


ͼ1£ºÖØ×éÈËIL-21µ°°×£¨GMP-TL509£©´¿¶È¼ì²âSDS-PAGE


ͼ2£ºÖØ×éÈËIL-21µ°°×£¨GMP-TL509£©´Ì¼¤NK-92ϸ°û·ÖÃÚIFN-¦Ã,²»Í¬Åú´Î»îÐÔÎȶ¨²âÊÔ


²Î¿¼ÎÄÏ×


¡¾1¡¿ Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014 May;13(5):379-95.


¡¾2¡¿Quast I, Dvorscek AR, Pattaroni C, Steiner TM, McKenzie CI, Pitt C, O'Donnell K, Ding Z, Hill DL, Brink R, Robinson MJ, Zotos D, Tarlinton DM. Interleukin-21, acting beyond the immunological synapse, independently controls T follicular helper and germinal center B cells. Immunity. 2022 Aug 9;55(8):1414-1430.e5.


¡¾3¡¿Zander R, Kasmani MY, Chen Y, Topchyan P, Shen J, Zheng S, Burns R, Ingram J, Cui C, Joshi N, Craft J, Zajac A, Cui W. Tfh-cell-derived interleukin 21 sustains effector CD8+ T cell responses during chronic viral infection. Immunity. 2022 Mar 8;55(3):475-493.e5.


¡¾4¡¿Deng S, Sun Z, Qiao J, Liang Y, Liu L, Dong C, Shen A, Wang Y, Tang H, Fu YX, Peng H. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells. JCI Insight. 2020 Apr 9;5(7):e132000.



¹ØÓÚ¾º¼¼±¦¹ÙÍø

±±¾©¾º¼¼±¦¹ÙÍøÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾£¬×¨×¢Ï¸°ûºÍ»ùÒòÖÎÁÆ£¨CGT£©GMP¼¶Ô­ÁÏÊÔ¼ÁÑз¢¼°Éú²ú£¬ÎªCGTÓû§Ìṩ²úÆ·Óë·þÎñµÄÕûÌå½â¾ö·½°¸¡£²úÆ·Éæ¼°Ï¸°û·ÖÑ¡´ÅÖéÊÔ¼Á¡¢ÕæºË/Ô­ºËÖØ×éµ°°×¡¢ÎÞѪÇåÅàÑø»ù¡¢Ï¸°ûÅàÑøÊÔ¼ÁºÐµÈ¡£

¹«Ë¾½¨ÓÐ3200©OµÄÑз¢ÊµÑéÊÒ¼°GMP¼¶½à¾»³µ¼ä£¬°üÀ¨Ï¸°û·ÖÑ¡´ÅÖ鿪·¢Æ½Ì¨¡¢ÕæºËÓëÔ­ºËµ°°×±í´ï¹¤³Ìƽ̨¡¢ÎÞѪÇåÅàÑø»ù¿ª·¢Æ½Ì¨£¬Í¨¹ýISO13485ºÍISO9001Ë«ÖÊÁ¿ÌåϵÈÏÖ¤£¬²¿·Ö²úÆ·ÒÑ»ñÃÀ¹úFDA DMF±¸°¸¡£

¸ü¶à×ÊѶ

·ÖÑ¡´ÅÖé/ϸ°ûÒò×Ó/ÖØ×éµ°°×/µ¥¿Ë¡¿¹Ìå×ÊÁÏ»ñȡϸ°ûÅàÑøÊÔ¼Á/ÅàÑø»ù×ÊÁÏ»ñÈ¡
·ÖÑ¡´ÅÖé/ϸ°ûÒò×Ó/ÖØ×éµ°°×/µ¥¿Ë¡¿¹ÌåÔÚÏß¹µÍ¨Ï¸°ûÅàÑøÊÔ¼Á/ÅàÑø»ùÔÚÏß¹µÍ¨
×ÉѯÈÈÏß

ÖÜÒ» ÖÁ ÖÜÎå
09:00-17:30

400-010-5556 18610367518 QQ:2850881917
΢ÐÅ×Éѯ

רҵɨÂë»ñÈ¡
רҵ×Éѯ·þÎñ

¾º¼¼±¦¹ÙÍø¹«ÖÚºÅ-·þÎñºÅ
ÔÚÏß×Éѯ ×Éѯ
¾º¼¼±¦¹ÙÍøÉúÎïÍøÕ¾¾º¼¼±¦¹ÙÍø¾º¼¼±¦¹ÙÍø
ÔÚÏßÁôÑÔ
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿